Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry
Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean f...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 15, 2024
|
| In: |
RMD Open
Year: 2024, Volume: 10, Issue: 1, Pages: 1-15 |
| ISSN: | 2056-5933 |
| DOI: | 10.1136/rmdopen-2023-003890 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/rmdopen-2023-003890 Verlag, lizenzpflichtig, Volltext: https://rmdopen.bmj.com/content/10/1/e003890 
|
| Author Notes: | Jasmin B. Kuemmerle-Deschner, Tilmann Kallinich, Joerg Henes, Birgit Kortus-Götze, Prasad T. Oommen, Juergen Rech, Tobias Krickau, Frank Weller-Heinemann, Gerd Horneff, Aleš Janda, Ivan Foeldvari, Catharina Schuetz, Frank Dressler, Michael Borte, Markus Hufnagel, Florian Meier, Michael Fiene, Ioana Andreica, Julia Weber-Arden, Norbert Blank |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1902274008 | ||
| 003 | DE-627 | ||
| 005 | 20250325052448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240910s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2023-003890 |2 doi | |
| 035 | |a (DE-627)1902274008 | ||
| 035 | |a (DE-599)KXP1902274008 | ||
| 035 | |a (OCoLC)1475311293 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kümmerle-Deschner, Jasmin |d 1964- |e VerfasserIn |0 (DE-588)102241092X |0 (DE-627)716964546 |0 (DE-576)17222442X |4 aut | |
| 245 | 1 | 0 | |a Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases |b results from the interim analysis of the RELIANCE registry |c Jasmin B. Kuemmerle-Deschner, Tilmann Kallinich, Joerg Henes, Birgit Kortus-Götze, Prasad T. Oommen, Juergen Rech, Tobias Krickau, Frank Weller-Heinemann, Gerd Horneff, Aleš Janda, Ivan Foeldvari, Catharina Schuetz, Frank Dressler, Michael Borte, Markus Hufnagel, Florian Meier, Michael Fiene, Ioana Andreica, Julia Weber-Arden, Norbert Blank |
| 264 | 1 | |c February 15, 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.09.2024 | ||
| 520 | |a Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), tumour-necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate-kinase deficiency (MKD)/hyperimmunoglobulin-D syndrome (HIDS). - Methods From September 2017 for patients with CAPS, and June 2018 for patients with FMF, TRAPS or MKD/HIDS, the registry enrolled paediatric (aged ≥2 years) and adult patients (aged ≥18 years) receiving canakinumab as part of their routine medical care. Safety, canakinumab dose, disease activity and quality of life outcome measures were evaluated at baseline and every 6 months until end of study visit. - Results At the analysis cut-off date (December 2020), 168 patients (91 CAPS, 54 FMF, 16 TRAPS and 7 MKD/HIDS) were enrolled. 85 (50.9%) patients were female and 72 (43.1%) were children (<18 years). The median patient age was 20.0 years (range 2.0-79.0 years). In the CAPS cohort, serious infections and serious adverse drug-reactions were more common in patients receiving higher than the recommended starting dose (SD) of canakinumab. A trend to receive >SD of canakinumab was observed in the pooled population. The majority of patients were reported as having either absent or mild/moderate disease activity (physician’s global assessment) from baseline to Month 30, with a stable proportion of patients (~70%) in remission under canakinumab treatment. Patient-reported disease activity (Visual Analogue Scale (VAS), Autoinflammatory Disease Activity Index), fatigue (VAS); markers of inflammation (C-reactive protein, serum amyloid A and erythrocyte sedimentation rate) remained well-controlled throughout. - Conclusion Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS. | ||
| 650 | 4 | |a Cryopyrin-Associated Periodic Syndromes | |
| 650 | 4 | |a Familial Mediterranean Fever | |
| 650 | 4 | |a Inflammation | |
| 700 | 1 | |a Kallinich, Tilmann |d 1968- |e VerfasserIn |0 (DE-588)118119443 |0 (DE-627)694685623 |0 (DE-576)177907509 |4 aut | |
| 700 | 1 | |a Henes, Joerg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kortus-Götze, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Oommen, Prasad |e VerfasserIn |0 (DE-588)1253028486 |0 (DE-627)1794881077 |4 aut | |
| 700 | 1 | |8 2\p |a Rech, Jürgen |e VerfasserIn |0 (DE-588)121212667X |0 (DE-627)1700736612 |4 aut | |
| 700 | 1 | |a Krickau, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weller-Heinemann, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |8 3\p |a Horneff, Gerd |e VerfasserIn |0 (DE-588)1227859813 |0 (DE-627)1749055775 |4 aut | |
| 700 | 1 | |8 4\p |a Janda, Ales̆ |d 1974- |e VerfasserIn |0 (DE-588)1144918359 |0 (DE-627)1005051356 |0 (DE-576)495521647 |4 aut | |
| 700 | 1 | |a Foeldvari, Ivan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schuetz, Catharina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dressler, Frank |d 1960- |e VerfasserIn |0 (DE-588)1037381831 |0 (DE-627)755547535 |0 (DE-576)391391844 |4 aut | |
| 700 | 1 | |a Borte, Michael |d 1953- |e VerfasserIn |0 (DE-588)109784987 |0 (DE-627)519013204 |0 (DE-576)185696783 |4 aut | |
| 700 | 1 | |a Hufnagel, Markus |d 1964- |e VerfasserIn |0 (DE-588)141005815 |0 (DE-627)623820137 |0 (DE-576)172510392 |4 aut | |
| 700 | 1 | |a Meier, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fiene, Michael |d 1966- |e VerfasserIn |0 (DE-588)1033514640 |0 (DE-627)741332221 |0 (DE-576)381119947 |4 aut | |
| 700 | 1 | |a Andreica, Ioana |d 1974- |e VerfasserIn |0 (DE-588)1222524791 |0 (DE-627)1741554489 |4 aut | |
| 700 | 1 | |a Weber-Arden, Julia |d 1964- |e VerfasserIn |0 (DE-588)121957411 |0 (DE-627)705714950 |0 (DE-576)293017425 |4 aut | |
| 700 | 1 | |a Blank, Norbert |d 1964- |e VerfasserIn |0 (DE-588)115586032 |0 (DE-627)691431507 |0 (DE-576)289963508 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD Open |d London : BMJ Publishing Group, 2015 |g 10(2024), 1, Artikel-ID e003890, Seite 1-15 |h Online-Ressource |w (DE-627)819493627 |w (DE-600)2812592-7 |w (DE-576)427161614 |x 2056-5933 |7 nnas |a Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases results from the interim analysis of the RELIANCE registry |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:1 |g elocationid:e003890 |g pages:1-15 |g extent:15 |a Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases results from the interim analysis of the RELIANCE registry |
| 856 | 4 | 0 | |u https://doi.org/10.1136/rmdopen-2023-003890 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://rmdopen.bmj.com/content/10/1/e003890 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240910 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 115586032 |a Blank, Norbert |m 115586032:Blank, Norbert |d 910000 |d 910100 |d 50000 |e 910000PB115586032 |e 910100PB115586032 |e 50000PB115586032 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 20 |y j | ||
| 999 | |a KXP-PPN1902274008 |e 4578550354 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Jasmin B. Kuemmerle-Deschner, Tilmann Kallinich, Joerg Henes, Birgit Kortus-Götze, Prasad T. Oommen, Juergen Rech, Tobias Krickau, Frank Weller-Heinemann, Gerd Horneff, Aleš Janda, Ivan Foeldvari, Catharina Schuetz, Frank Dressler, Michael Borte, Markus Hufnagel, Florian Meier, Michael Fiene, Ioana Andreica, Julia Weber-Arden, Norbert Blank"]},"person":[{"display":"Kümmerle-Deschner, Jasmin","given":"Jasmin","role":"aut","family":"Kümmerle-Deschner"},{"role":"aut","given":"Tilmann","display":"Kallinich, Tilmann","family":"Kallinich"},{"given":"Joerg","role":"aut","display":"Henes, Joerg","family":"Henes"},{"family":"Kortus-Götze","display":"Kortus-Götze, Birgit","role":"aut","given":"Birgit"},{"role":"aut","given":"Prasad","display":"Oommen, Prasad","family":"Oommen"},{"role":"aut","given":"Jürgen","display":"Rech, Jürgen","family":"Rech"},{"given":"Tobias","role":"aut","display":"Krickau, Tobias","family":"Krickau"},{"family":"Weller-Heinemann","display":"Weller-Heinemann, Frank","role":"aut","given":"Frank"},{"family":"Horneff","display":"Horneff, Gerd","role":"aut","given":"Gerd"},{"display":"Janda, Ales̆","given":"Ales̆","role":"aut","family":"Janda"},{"given":"Ivan","role":"aut","display":"Foeldvari, Ivan","family":"Foeldvari"},{"given":"Catharina","role":"aut","display":"Schuetz, Catharina","family":"Schuetz"},{"display":"Dressler, Frank","role":"aut","given":"Frank","family":"Dressler"},{"display":"Borte, Michael","given":"Michael","role":"aut","family":"Borte"},{"family":"Hufnagel","given":"Markus","role":"aut","display":"Hufnagel, Markus"},{"display":"Meier, Florian","given":"Florian","role":"aut","family":"Meier"},{"role":"aut","given":"Michael","display":"Fiene, Michael","family":"Fiene"},{"display":"Andreica, Ioana","role":"aut","given":"Ioana","family":"Andreica"},{"display":"Weber-Arden, Julia","given":"Julia","role":"aut","family":"Weber-Arden"},{"family":"Blank","display":"Blank, Norbert","role":"aut","given":"Norbert"}],"recId":"1902274008","origin":[{"dateIssuedDisp":"February 15, 2024","dateIssuedKey":"2024"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1136/rmdopen-2023-003890"],"eki":["1902274008"]},"physDesc":[{"noteIll":"Illustrationen","extent":"15 S."}],"relHost":[{"title":[{"title_sort":"RMD Open","title":"RMD Open"}],"language":["eng"],"part":{"pages":"1-15","extent":"15","issue":"1","text":"10(2024), 1, Artikel-ID e003890, Seite 1-15","year":"2024","volume":"10"},"pubHistory":["1.2015 -"],"id":{"zdb":["2812592-7"],"issn":["2056-5933"],"eki":["819493627"]},"disp":"Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases results from the interim analysis of the RELIANCE registryRMD Open","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 17.08.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Rheumatic & musculoskeletal diseases"}],"recId":"819493627","origin":[{"publisherPlace":"London","dateIssuedDisp":"2015-","publisher":"BMJ Publishing Group","dateIssuedKey":"2015"}]}],"note":["Gesehen am 10.09.2024"],"title":[{"title_sort":"Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases","subtitle":"results from the interim analysis of the RELIANCE registry","title":"Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases"}],"language":["eng"]} | ||
| SRT | |a KUEMMERLEDLONGTERMSA1520 | ||